News
-
-
-
COMMUNIQUÉ DE PRESSE
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. in talks with animal health partners to bring Canalevia to global market for general diarrhea in dogs. CEO presents at conference to discuss updates on Canalevia-CA1 -
-
-
COMMUNIQUÉ DE PRESSE
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indic
Jaguar Health announces agreement for research on coca plants to develop plant-based drugs for mental health and CNS indications, focusing on fair benefits sharing and traditional medicine -
-
-
COMMUNIQUÉ DE PRESSE
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
Initial proof-of-concept results show crofelemer's efficacy in reducing TPN for intestinal failure patients. Jaguar seeking partnerships for drug development and commercialization -
